Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489718 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL29913716 | 0.84 | MAPK1 (0.34) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL21544112 | 0.84 | MAPK1 (0.34) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL682486 | 0.81 | MAPK1 (0.43) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL29517897 | 0.78 | SLC6A4 (0.47) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL246292 | 0.78 | SLC6A4 (0.47) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL16955540 | 0.76 | ALDH1A1 (0.39) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL4334089 | 0.76 | KMT2A (0.40) | ALDH1A1L3MBTL1TSHRMAPTLMNA | |
| SCHEMBL364614 | 0.76 | MEN1 (0.44) | ALDH1A1MAPK1L3MBTL1TDP1TSHR | |
| SCHEMBL127803 | 0.76 | ALOX15 (0.44) | ALDH1A1MAPK1L3MBTL1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12247032-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases | GENENTECH, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240279240-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-08-22 | — | — | US | disclosed |
| EP-4308122-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981459-A | Heterocyclic derivatives as janus kinase inhibitors | 奇斯药制品公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | GENENTECH, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-110650959-B | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230016791-A1 | INHALABLE DRY POWDER AND AEROSOL FORMULATIONS OF JAK INHIBITORS | GENENTECH, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| WO-2018215389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-11-29 | — | — | WO | disclosed |
| US-20180333416-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| EP-3380474-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-10-03 | — | — | EP | disclosed |
| US-20180265515-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| CN-108368116-A | Janus kinase inhibitors, its composition and purposes | 豪夫迈·罗氏有限公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167123-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1515/4885MAPK1 103/4885L3MBTL1 1913/4885 |
| US-20230016791-A1 | INHALABLE DRY POWDER AND AEROSOL FORMULATIONS OF JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 3286/4885MAPK1 158/4885L3MBTL1 2151/4885 |
| US-20180333416-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 2575/4885MAPK1 135/4885L3MBTL1 1725/4885 |
| US-20180265515-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1588/4885MAPK1 69/4885L3MBTL1 3274/4885 |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 2322/4885MAPK1 132/4885L3MBTL1 2353/4885 |
| US-12528812-B2 | Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof | JAK1, JAK2, CNKSR1 | ALDH1A1 2304/4885MAPK1 21/4885L3MBTL1 2845/4885 |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | JAK2, JAK1, JAK3 | ALDH1A1 2575/4885MAPK1 135/4885L3MBTL1 1725/4885 |
| US-20240279240-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | ALDH1A1 3533/4885MAPK1 94/4885L3MBTL1 4234/4885 |
| US-12247032-B2 | Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases | JAK1, JAK2, JAK3 | ALDH1A1 1508/4885MAPK1 56/4885L3MBTL1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.